B-Cell Engineering with Portal's Platform

Macrocycles

Who this is for

Lorem Ipsum

Opportunities

Lorem Ipsum
Lorem Ipsum

Results obtained

Lorem Ipsum
Lorem Ipsum

Start delivering now. Experimentally proven delivery workflows for live-cell screening and functional engineering with macrocycles.

Workflow	Example Cell Type	Cargo	Readout	What this Unlocks
Lorem	Lorem	Lorem	Lorem

Highlighted Data and Applications

The percentage of live HeLa cells remains stable across escalating macrocycle concentrations (0 to 0.2 mg/ml) when utilizing the Boost delivery platform (administered without additional cargo).

Sustained Viability in HeLa Cells Across Escalating Macrocycle Doses

Portal's technology enables macrocycle delivery without compromising cell health. When evaluated across a range of escalating macrocycle concentrations, HeLa cell viability remained stable throughout. At the untreated baseline control (0 mg/mL), cell viability was approximately 80%. As the macrocycle dose escalated through 0.025 mg/mL and 0.1 mg/mL, viability remained nearly identical to baseline, and no significant drop-off was observed even at the maximum concentration of 0.2 mg/mL. This consistent viability across the full 0–0.2 mg/mL dosing range highlights the exceptionally low cytotoxicity of Portal's delivery method.

The percentage of FITC-positive live cells shows a strong, dose-dependent increase, achieving near 100% intracellular delivery efficiency at macrocycle concentrations of 0.1 mg/ml and 0.2 mg/ml.

Dose-Dependent Intracellular Delivery in HeLa Cells.

Intracellular delivery of macrocycles into HeLa cells was achieved with efficiency. Following delivery, the percentage of FITC-positive live cells showed a strong, clear, dose dependent increase. Untreated cells (0 mg/ml) exhibited 0% delivery, treated cells achieved approximately 50% delivery efficiency at lowest active dose of 0.025 mg/ml. This efficiency scaled up ~80% at 0.05 mg/ml, and achieved near-total intracellular delivery–approximtely 90% to 100% efficiency–at the peak macrocycle concentrations of 0.1 mg/ml and 0.2 mg/ml. These results demonstrate the platform’s ability to drive cargo uptake at scale while preserving overall cell integrity.

Visual Confirmation of Uptake in HEK293 Cells. Fluorescence microscopy (FITC and Transmitted light) of HEK293 cells reveals distinct intracellular accumulation of FITC-labeled macrocycles in the Boost-treated group compared to untreated baseline.

Delivery of Macrocycle to HEK293 cells

HEK293 cells are treated with FITC-labeled macrocycles utilizing Portal’s delivery technology (Boosting). Fluorescence microscopy provides visual evidence of successful macrocycle delivery into HEK293 cells. While untreated baseline groups show no fluorescence, the Boost-treated cells exhibit robust intracellular accumulation of FITC-labeled macrocycles.

Quantitative Delivery Success in HEK293 Cells. Flow cytometry data corroborates the visual microscopy, demonstrating high percentages of FITC-positive live cells while maintaining a high percentage of overall live cells.

Macrocycle Delivery and Maintained Viability in HEK293 Cells

Flow cytometry demonstrates that the Portal delivery platform achieves massive efficiency while protecting overall HEK293 cell health. Quantitative analysis reveals that approximately 80% of treated cells successfully took up macrocycles(measured as FITC-positive live cells), compared to the 0% delivery seen in the untreated baseline. Crucially, this high-volume intracellular delivery was accomplished while maintaining a strong overall cell viability of roughly 80% (compared to the ~100% viability of the untreated control). These metrics demonstrate the platform's ability to balance highly efficient cargo delivery with the preservation of a robust, living cell population.